StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.69+0.06 (+3.68%)

Close on Nov 18, 2026Market cap $174.74MP/E –Yield –

Inovio Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Inovio Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$80.58M. For fiscal 2025 it was -$88.63M. The highest annual figure on record is -$11.94M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.63M–
FY2024Dec 31, 2024-$104.08M–
FY2023Dec 31, 2023-$124.37M–
FY2022Dec 31, 2022-$216.22M–
FY2021Dec 31, 2021-$215.71M–
FY2020Dec 31, 2020-$177.98M–
FY2019Dec 31, 2019-$97.85M–
FY2018Dec 31, 2018-$73.55M–
FY2017Dec 31, 2017-$63.21M–
FY2016Dec 31, 2016-$62.56M–
FY2015Dec 31, 2015-$12.44M–
FY2014Dec 31, 2014-$29.82M–
FY2013Dec 31, 2013-$15.38M–
FY2012Dec 31, 2012-$22.31M–
FY2011Dec 31, 2011-$19.76M–
FY2010Dec 31, 2010-$11.94M–
FY2009Dec 31, 2009-$14.08M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.05M–
Q1 FY2026Mar 31, 2026-$21.59M–
Q4 FY2025Dec 31, 2025-$19.37M–
Q3 FY2025Sep 30, 2025-$21.57M–
Q2 FY2025Jun 30, 2025-$20.81M–
Q1 FY2025Mar 31, 2025-$26.87M–
Q4 FY2024Dec 31, 2024-$19.66M–
Q3 FY2024Sep 30, 2024-$27.44M–
Q2 FY2024Jun 30, 2024-$28.21M–
Q1 FY2024Mar 31, 2024-$28.76M–
Q4 FY2023Dec 31, 2023-$26.28M–
Q3 FY2023Sep 30, 2023-$29.11M–
Q2 FY2023Jun 30, 2023-$32.31M–
Q1 FY2023Mar 31, 2023-$36.66M–
Q4 FY2022Dec 31, 2022-$36.34M–
Q3 FY2022Sep 30, 2022-$67.47M–
Q2 FY2022Jun 30, 2022-$50.53M–
Q1 FY2022Mar 31, 2022-$61.88M–
Q4 FY2021Dec 31, 2021-$37.89M–
Q3 FY2021Sep 30, 2021-$46.49M–
Q2 FY2021Jun 30, 2021-$78.46M–
Q1 FY2021Mar 31, 2021-$52.87M–
Q4 FY2020Dec 31, 2020-$51.22M–
Q3 FY2020Sep 30, 2020-$74.16M–
Q2 FY2020Jun 30, 2020-$27.15M–
Q1 FY2020Mar 31, 2020-$25.45M–
Q4 FY2019Dec 31, 2019-$13.74M–
Q3 FY2019Sep 30, 2019-$27.73M–
Q2 FY2019Jun 30, 2019-$23.92M–
Q1 FY2019Mar 31, 2019-$32.45M–
Q4 FY2018Dec 31, 2018-$17.28M–
Q3 FY2018Sep 30, 2018-$24.67M–
Q2 FY2018Jun 30, 2018-$19.02M–
Q1 FY2018Mar 31, 2018-$12.58M–
Q4 FY2017Dec 31, 2017-$13.95M–
Q3 FY2017Sep 30, 2017-$17.31M–
Q2 FY2017Jun 30, 2017-$16.72M–
Q1 FY2017Mar 31, 2017-$15.23M–
Q4 FY2016Dec 31, 2016-$14.90M–
Q3 FY2016Sep 30, 2016-$18.64M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?